Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated reports developments in diagnostic information services, laboratory testing and related healthcare data offerings. Company news commonly covers financial results, guidance, clinical testing activity, consumer access through questhealth.com and MyQuest, and advanced diagnostics such as Quest AD-Detect blood tests for Alzheimer’s disease and Haystack MRD ctDNA testing for oncology research.
Updates also include health system collaborations, Co-Lab Solutions activity, clinical trial and research partnerships, AI-enabled patient tools, board and executive appointments, dividends, share repurchases, debt financing and shareholder voting matters.
Quest Diagnostics (NYSE: DGX) announced that its Board of Directors has declared a quarterly cash dividend of $0.86 per share.
The dividend is payable on July 22, 2026 to shareholders of record as of July 8, 2026.
Quest Diagnostics (NYSE: DGX) priced a public offering of $500 million aggregate principal amount of 5.000% senior notes due 2036 under its shelf registration. The company expects net proceeds at closing on May 6, 2026, to be used for general corporate purposes, which may include repaying indebtedness.
The announcement notes the company may repay its $500 million aggregate principal amount of 3.45% senior notes maturing on June 1, 2026. The offering will be made via a prospectus supplement and base prospectus; bookrunners include Goldman Sachs, J.P. Morgan, and Mizuho.
Quest Diagnostics (NYSE: DGX) reported first quarter 2026 results: net revenues $2.90B (+9.2% YoY) and reported diluted EPS $2.24 (+15.5% YoY), with adjusted diluted EPS $2.50 (+13.1%).
The company raised full‑year 2026 guidance: reported EPS $9.58–$9.78 and adjusted EPS $10.63–$10.83; net revenues now $11.78–$11.90B.
Quest Diagnostics (NYSE: DGX) and City of Hope launched a multi-year research collaboration to evaluate the Haystack MRD® circulating-tumor DNA test in breast, colorectal, ovarian and prostate cancers.
The study will enroll about 500 patients across 14 City of Hope sites, producing thousands of longitudinal ctDNA measurements to assess MRD detection, treatment response monitoring, and earlier recurrence identification.
Quest Diagnostics (NYSE: DGX) will report first quarter 2026 financial results on April 21, 2026 before the market opens and will host a conference call at 8:30 a.m. ET.
The live webcast, earnings release, dial‑in numbers, passcode, and replay details will be posted at the company investor website. Telephone replay is available from about 10:30 a.m. ET on April 21 until midnight ET on May 5, 2026.
Investors are encouraged to review the company's SEC filings for risk factors and historical financial information.
Quest Diagnostics (NYSE: DGX) elected Timothy Wentworth to its board of directors on March 12, 2026, bringing the board to eleven members. Mr. Wentworth is a former CEO of Walgreens Boots Alliance, Evernorth, and Express Scripts with extensive pharmacy, health plan, and operations experience.
The company said his background in employer, plan, and consumer channels and HR and operations expertise will support Quest's diagnostic and health-services strategy.
Quest Diagnostics (NYSE: DGX) launched Quest AI Companion on March 2, 2026, an AI chat feature in MyQuest that analyzes up to five years of Quest lab data to explain results, highlight trends, and help users prepare questions for clinicians.
Powered by Google’s Gemini models via a strategic Google Cloud collaboration (established March 2025), the tool operates within the HIPAA-compliant MyQuest platform and is available to adult users; it is educational and not a substitute for professional medical advice.
Quest Diagnostics (NYSE: DGX) named Benjamin Beauvalot senior vice president, chief strategy and M&A officer, effective Feb. 26, 2026. He brings more than 20 years of strategy, M&A and transformation experience from Danaher, Patheon and Banner Life Sciences.
Mr. Beauvalot will lead growth strategy, mergers and acquisitions, strategic partnerships and integrations, reporting to Jim Davis and joining the executive leadership team. He succeeds Dermot Shorten, who will retire in Q2 2026 after overseeing nearly 80 business combinations, including about 20 hospital outreach lab acquisitions.
Quest Diagnostics (NYSE: DGX) announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak at the Leerink 2026 Global Healthcare Conference in Miami on March 11, 2026 at 8:00 a.m. ET.
The fireside chat and Q&A will be webcast live on the company's investor relations site, with an archived replay available within 24 hours and accessible through March 25, 2026.
Quest Diagnostics (NYSE: DGX) reported fourth-quarter 2025 net revenues of $2.81 billion (up 7.1%) and full-year 2025 net revenues of $11.04 billion (up 11.8%). Reported diluted EPS was $2.18 for Q4 and $8.75 for full year; adjusted diluted EPS was $2.42 for Q4 and $9.85 for the year.
The company generated $1.89 billion of cash from operations in 2025, raised its quarterly dividend 7.5% to $0.86 per share, and provided 2026 guidance of $11.70–$11.82 billion in revenues and adjusted diluted EPS of $10.50–$10.70.